tradingkey.logo

NeuroOne Medical Technologies Corp

NMTC
0.734USD
+0.018+2.53%
收盤 12/19, 16:00美東報價延遲15分鐘
36.58M總市值
虧損本益比TTM

NeuroOne Medical Technologies Corp

0.734
+0.018+2.53%

關於 NeuroOne Medical Technologies Corp 公司

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

NeuroOne Medical Technologies Corp簡介

公司代碼NMTC
公司名稱NeuroOne Medical Technologies Corp
上市日期Nov 09, 2012
CEORosa (David A)
員工數量17
證券類型Ordinary Share
年結日Nov 09
公司地址7599 Anagram Dr
城市EDEN PRAIRIE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編55344-7399
電話19524261383
網址https://nmtc1.com/
公司代碼NMTC
上市日期Nov 09, 2012
CEORosa (David A)

NeuroOne Medical Technologies Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
615.75K
-0.40%
Mr. Mark Christianson
Mr. Mark Christianson
Co-Founder, Business Development Director, Medical Sales Liaison
Co-Founder, Business Development Director, Medical Sales Liaison
230.99K
-11.58%
Mr. Paul Buckman
Mr. Paul Buckman
Independent Chairman of the Board
Independent Chairman of the Board
136.80K
+25.48%
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Independent Director
Independent Director
114.41K
+32.06%
Mr. Steve Mertens
Mr. Steve Mertens
Chief Technology Officer
Chief Technology Officer
101.75K
-0.88%
Mr. Edward (Ed) Andrle
Mr. Edward (Ed) Andrle
Independent Director
Independent Director
92.00K
+43.25%
Mr. Chris Donovan
Mr. Chris Donovan
Investor Relations
Investor Relations
--
--
Ms. Emily Johns
Ms. Emily Johns
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Mr. Ronald (Ron) Mcclurg
Mr. Ronald (Ron) Mcclurg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher R. Volker
Mr. Christopher R. Volker
Chief Operating Officer
Chief Operating Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
615.75K
-0.40%
Mr. Mark Christianson
Mr. Mark Christianson
Co-Founder, Business Development Director, Medical Sales Liaison
Co-Founder, Business Development Director, Medical Sales Liaison
230.99K
-11.58%
Mr. Paul Buckman
Mr. Paul Buckman
Independent Chairman of the Board
Independent Chairman of the Board
136.80K
+25.48%
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Independent Director
Independent Director
114.41K
+32.06%
Mr. Steve Mertens
Mr. Steve Mertens
Chief Technology Officer
Chief Technology Officer
101.75K
-0.88%
Mr. Edward (Ed) Andrle
Mr. Edward (Ed) Andrle
Independent Director
Independent Director
92.00K
+43.25%

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Merchant Adventure Fund LP
8.33%
Bleichroeder LP
7.93%
Manchester Management Company, L.L.C.
4.69%
Sio Capital Management, LLC
4.68%
Bard Associates Inc.
3.67%
其他
70.69%
持股股東
持股股東
佔比
Merchant Adventure Fund LP
8.33%
Bleichroeder LP
7.93%
Manchester Management Company, L.L.C.
4.69%
Sio Capital Management, LLC
4.68%
Bard Associates Inc.
3.67%
其他
70.69%
股東類型
持股股東
佔比
Investment Advisor
18.22%
Hedge Fund
11.19%
Corporation
8.33%
Individual Investor
4.14%
Investment Advisor/Hedge Fund
3.26%
Research Firm
0.55%
Venture Capital
0.04%
其他
54.27%

機構持股

更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
51
17.15M
34.30%
+9.56M
2025Q2
52
13.28M
26.66%
+2.81M
2025Q1
54
11.51M
24.26%
+968.46K
2024Q4
55
12.46M
40.67%
+1.38M
2024Q3
55
11.22M
39.84%
+2.23M
2024Q2
51
10.72M
41.07%
+2.35M
2024Q1
52
11.45M
45.01%
+2.75M
2023Q4
57
9.37M
38.68%
+871.77K
2023Q3
54
7.90M
33.50%
+2.01M
2023Q2
48
4.40M
25.73%
-1.65M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Merchant Adventure Fund LP
4.20M
8.4%
+2.95M
+236.00%
Dec 31, 2024
Bleichroeder LP
4.00M
8%
+4.00M
--
Jun 30, 2025
Manchester Management Company, L.L.C.
2.36M
4.73%
+864.05K
+57.60%
Jan 03, 2025
Sio Capital Management, LLC
3.52M
7.05%
+3.52M
--
Jun 30, 2025
Bard Associates Inc.
1.85M
3.71%
+1.85M
--
Jun 30, 2025
The Vanguard Group, Inc.
1.20M
2.41%
+91.91K
+8.27%
Jun 30, 2025
Perkins Capital Management, Inc.
1.50M
3%
+1.50M
--
Jun 30, 2025
AWM Investment Company, Inc.
916.67K
1.83%
-250.00K
-21.43%
Jun 30, 2025
Renaissance Technologies LLC
468.90K
0.94%
+468.90K
--
Jun 30, 2025
Rosa (David A)
615.75K
1.23%
-2.46K
-0.40%
Sep 30, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

NeuroOne Medical Technologies Corp的前五大股東是誰?

NeuroOne Medical Technologies Corp的前五大股東如下:
Merchant Adventure Fund LP
持有股份:4.20M
佔總股份比例:8.40%。
Bleichroeder LP
持有股份:4.00M
佔總股份比例:8.00%。
Manchester Management Company, L.L.C.
持有股份:2.36M
佔總股份比例:4.73%。
Sio Capital Management, LLC
持有股份:3.52M
佔總股份比例:7.05%。
Bard Associates Inc.
持有股份:1.85M
佔總股份比例:3.71%。

NeuroOne Medical Technologies Corp的前三大股東類型是什麼?

NeuroOne Medical Technologies Corp 的前三大股東類型分別是:
Merchant Adventure Fund LP
Bleichroeder LP
Manchester Management Company, L.L.C.

有多少機構持有NeuroOne Medical Technologies Corp(NMTC)的股份?

截至2025Q3,共有51家機構持有NeuroOne Medical Technologies Corp的股份,合計持有的股份價值約為17.15M,占公司總股份的34.30% 。與2025Q2相比,機構持股有所增加,增幅為7.64%。

哪個業務部門對NeuroOne Medical Technologies Corp的收入貢獻最大?

在--,--業務部門對NeuroOne Medical Technologies Corp的收入貢獻最大,創收--,占總收入的--% 。
KeyAI